Want to keep yourself up to date with the latest news from The Healthcare Technology Report.?
Subscribe using the "Follow" button below and we provide you with customized updates, via topic or tag, that get delivered to your email address, your smartphone or on your dedicated news page on follow.it.
You can unsubscribe at any time painlessly.
Title of The Healthcare Technology Report.: "The Healthcare Technology Report. | The Healthcare Technology Report is your comprehensive source for business news, investment activity and corporate actions related to the software and SaaS sectors"
Is this your feed? Claim it!
Suki has secured $90 million in Series E financing to expand its healthcare AI capabilities beyond clinical documentation. Patient encounters supported by its technology increased more than 190% year over year in 2026, while revenue doubled in 2025 and is on track for similar growth this year, according to the company.
New investors Healthier Capital, Crosslink Capital...
The Rockefeller Foundation and OpenAI Foundation have launched a $50 million initiative to help cities use AI to improve public services, from forecasting floods and anticipating disease outbreaks to connecting residents with benefits. Called Cities Deliver, the program will award grants ranging from $500,000 to $2 million to eligible nonprofit and civil society organizations...
Commure has appointed Nick Apeland President of Go-to-Market, bringing in an executive who helped build Qualtrics’ healthcare business to more than 10,000 customers. He will lead commercial efforts across administrative, clinical, and financial AI products used by more than 500 health systems and practices.
Previously, he led the regulated business at Qualtrics, includ...
Long after a patient leaves the hospital, another important part of their visit is still underway. Medical coders must translate the care they received into standardized codes before the hospital can submit an insurance claim. It’s complicated work, and a shortage of experienced coders is making it increasingly difficult for healthcare organizations to keep up.
Nym CEO...
CSL has agreed to pay Alentis Therapeutics $355 million upfront, with another $1.2 billion possible in commercial milestones, to jointly develop and commercialize an experimental treatment for rare kidney and liver diseases. The partnership centers on lixudebart, an investigational antibody designed to target claudin-1, a protein involved in inflammation and tissue scarring. ...